New Delhi: India saw a drop in Coronavirus cases for first time since April 21, as the country recorded 2.81 lakh fresh cases of Covid in last 24 hours taking the total tally of Covid-19 infections to 2,49,65,463, according to the Union health ministry data updated on Monday.
On Monday, the daily Covid cases reported in the country fell below the 3-lakh mark for the first time since April 21.
The number of active cases stands at 35,16,997, accounting for 14.09 per cent of the total infections. The national recovery rate has improved to 84.81 per cent, the data updated at 8am showed.
India’s cumulative recoveries have reached 2,11,74,076 with 3,78,741 patients recuperating in a span of 24 hours.
A total of 4,106 deaths were reported in on Monday, the ministry said. So far, a total of 2,74,390 deaths have been reported in the country.
India’s Covid-19 tally had crossed the 20-lakh mark on August 7, 30 lakh on August 23, 40 lakh on September 5 and 50 lakh on September 16. It went past 60 lakh on September 28, 70 lakh on October 11, crossed 80 lakh on October 29, 90 lakh on November 20 and surpassed the one-crore mark on December 19. India crossed the grim milestone of 2 crore Covid cases on May 4.
According to the ICMR, 31,64,23,658 samples have been tested up to May 16,2021 with 15,73,515 samples being tested on Sunday.
Meanwhile, the total number of Covid-19 vaccine doses administered in the country exceeded 18.3 crore on Sunday under phase 3 of the nationwide vaccination drive.
Today, Defence Minister Rajnath Singh and Union Health Minister Dr Harsh Vardhan released first batch of Anti-Covid drug 2-deoxy-D-glucose (2-DG) developed by Defence Research and Development Organisation (DRDO). The clinical trial results have shown that this molecule helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence. Higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in COVID patients. The drug will be of immense benefit to the people suffering from COVID-19.
Based on these results, Drugs Controller General of India’s (DCGI) Central Drugs Standard Control Organization (CDSCO) permitted Phase-II clinical trial of 2-DG in Covid-19 patients in May 2020.